Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
3.18M
-
Number of holders
-
36
-
Total 13F shares, excl. options
-
32.6M
-
Shares change
-
-1.27M
-
Total reported value, excl. options
-
$13M
-
Value change
-
-$495K
-
Number of buys
-
13
-
Number of sells
-
-18
-
Price
-
$0.40
Significant Holders of Passage BIO, Inc. - Common Stock, par value $0.0001 per share (PASG) as of Q2 2025
46 filings reported holding PASG - Passage BIO, Inc. - Common Stock, par value $0.0001 per share as of Q2 2025.
Passage BIO, Inc. - Common Stock, par value $0.0001 per share (PASG) has 36 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 32.6M shares
.
Largest 10 shareholders include Lynx1 Capital Management LP (9.26M shares), Vestal Point Capital, LP (6.1M shares), ORBIMED ADVISORS LLC (6.06M shares), Erste Asset Management GmbH (2.46M shares), VANGUARD GROUP INC (2.04M shares), TANG CAPITAL MANAGEMENT LLC (1.5M shares), RENAISSANCE TECHNOLOGIES LLC (1.42M shares), ACADIAN ASSET MANAGEMENT LLC (934K shares), BlackRock, Inc. (595K shares), and GEODE CAPITAL MANAGEMENT, LLC (539K shares).
This table shows the top 36 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.